Biopharmaceutical Classification System [BCS]

Biopharmaceutical Classification System [BCS]


The Biopharmaceutical Classification System was first developed by in 1995, by Amidon et al & his colleagues.

❖ Definition:

“The Biopharmaceutical Classification System is a scientific framework for classifying a drug substance based on its aqueous solubility & intestinal permeability & dissolution rate”.

❖To saved time fast screening is required so drug substances are classified on basis of solubility and permeability. This classification is called Biopharmaceutical Classification System.

FACTOR AFFECTING ON BCS

The Biopharmaceutical Classification System has been developed to provide a scientific approach to allow for to prediction in vivo pharmacokinetics of oral immediate release (IR) drug product by classifying drug compound based on their,

  1. SOLUBILITY
  2. PERMEABILITY
  3. DISSOLUTION
SOLUBILITY

❖The Maximum Amount of solute dissolved in a given solvent under standard conditions of temperature, pressure and pH.

❖ Solubility is the ability of the drug to be solution after dissolution

❖ The higher single unit dose is completely soluble in 250 ml at pH 1- 6.8 ( 37˚C ).

PERMEABILITY
❖Permeability of the drug to pass the biological membrane which is the lipophilic.

❖ Permeability  is  indirectly  based  on  the  extent  of  absorption  of  a  drug substance .

❖Drug substance is considered to be highly permeable, when the extent of absorption in human determined to be 90% or more of administered drug or compare to in vivo reference dose.

DISSOLUTION
❖ It is process in which solid substance solubilises in given solvent i.e mass transfer from solid surface to liquid phase.

❖ Using USP apparatus I at 100 rpm or USP apparatus II at 50 rpm .

❖ Dissolution Media [900 ml],
  1. 0.1 N HCl or simulated gastric fluid (pH 1.2) without enzyme.
  2. pH 4.5 buffer & pH 6.8 buffer.
  3. Simulated intestinal fluid without enzyme.
Biopharmaceutical Classification System for Drug

CLASS SOLUBILITY PERMEABILITY           EXAMPLES



Class – I     High                      High                         Metoprolol , Propranolol

Class – II     Low                      High                           Nifedipine,naproxen

Class – III   High                      Low                         Cimitidine,Metformin

Class – IV   Low                      Low                         Taxol,Clorthiazole


CLASS - I
❖ Ideal for oral route administration.

❖ Drug absorbed rapidly.

❖ Drug dissolved rapidly.

❖ Rapid therapeutic action.

❖ Bioavailability problem not expected for immediate release drug product.

❖ e.g. Metoprolol , Propranolol, Diltiazem.

CLASS - II

❖ Oral route for administration.

❖  Drug absorb rapidly.

❖  Drug dissolve slowly.

❖  Bioavailability is controlled by dosage form and rate of  release of the drug substance.

❖  e. g. Nifedipine, naproxen.

CLASS - III

❖ Oral route for administration.

❖ Drug absorbance is limited.

❖ Drug dissolve rapidly.

❖ Bioavailability is incomplete if drug is not release or  dissolve in absorption window.

❖ e. g. Cimitidine, Metformin,Insulin.

CLASS - IV

❖ Poorly absorbed by orally administration.

❖ Both solubility & permeability limitation.

❖ Low dissolution rate.

❖ Slow or low therapeutic action.

❖ An alternate route of administration may be needed.

❖ e. g. Taxol, Chlorthiazole, Cefexime Trihydrate.

APPLICATION

❖To predict in vivo performance of drug product using solubility and permeability measurements.
❖ Aid in earliest stages of drug discovery research.
❖ To use in biowaiver considerations.
❖For research scientist to decide upon which drug delivery technology to follow or develop.
❖ Also for the regulation of bioequivalence of the drug product during scale up and post approval.

CLASS BOUNDARIES

HIGHLY SOLUBLE

❖ The highest dose strength is soluble in < 250 ml water over a pH range of 1 to 7.5.
❖ The volume estimate - a glassful (8 ounce)

HIGHLY PERMEABLE

❖ When the extent of absorption in humans is determined to be > 90% of an administered dose.

RAPIDLY DISSOLVING

❖ When > 85% of the labeled amount of drug substance dissolves within 30 minutes using USP
apparatus I or II in a volume of < 900 ml buffer solutions.

BIOWAIVER

❖ “in vitro instead of in vivo bioequivalence testing”
❖ Definition:
It is an exemption from conducting human bioequivalence studies when the active ingredients meet certain solubility and permeability criteria in vitro and when the dissolution profile of the dosage form meets the requirements for an IR dosage form.

CRITERIA OF BIOWAIVER

❖ Rapid and similar dissolution

❖ High solubility

❖ High permeability

❖ Wide therapeutic window

❖ Excipient used in dosage form are same as those present in approved drug product

CONCLUSION

❖Biopharmaceutical classification  system  aims  to  provide  regulatory  tools  for replacing certain bio-equivalence studies by accurate in vivo dissolution tests.

❖The  in vivo pharmacokinetics of drug depends largely  on the solubility and permeability.

❖Many laboratories are engaged to find better means to estimates in vivo behavior of the drug after oral administration by using simple in vitro dissolution tests.












Post a Comment

0 Comments